FSTL3

Across TCGA pan-cancer cohorts, FSTL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FSTL3 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FSTL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FSTL3 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where FSTL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.396	0.895	.014	5	view →
LUAD	OS	Median	II,III,IV	0.782	1.000	.029	4	view →
PDAC	OS	Median	III,IV	0.235	0.608	.024	3	view →
LSCC	OS	Tertile	All	0.768	0.906	.031	2	view →
HNSC	OS	Tertile	III,IV	0.654	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FSTL3–CCRCC (OS)

Open the CCRCC breakdown →